Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Scientists Find 'Buckyball' Molecules To Deliver Gene Material

This article was originally published in PharmAsia News

Executive Summary

Researchers in Japan say they have been able to use nano-size carbon molecules to bind with genes as a way to insert genetic material into a body

You may also be interested in...



Young US FDA Office Of New Drug Policy Faces Regulatory Crucible In COVID-19

Created last year under the Office of New Drugs reorganization, ONDP works to promote regulatory consistency while fostering innovation – and reacting to unexpected challenges like the pandemic.

Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Veklury Takes Gilead Earnings On Wild Ride

The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel